ClearNote Health Validates 5hmC Signatures for Pancreatic Cancer Monitoring
Event summary
- ClearNote Health will present data on its Avantect Pancreatic Cancer Test at the AACR Conference on Pancreatic Cancer (Sept. 25-28, 2026).
- Study with Sheba Medical Center and Tel Aviv University analyzed 69 plasma samples, linking 5hmC signatures to treatment response and tumor subtype in BRCA-positive pancreatic cancer.
- Avantect Test combines 5hmC patterns, genomic features, and glycan biomarkers with machine learning algorithms for noninvasive monitoring.
- Test is being used in the NHS-led SAFE-D study and the PRECEDE Consortium for early pancreatic cancer detection.
The big picture
ClearNote Health's presentation underscores the growing importance of epigenomic markers in cancer monitoring, particularly for hard-to-detect tumors like pancreatic cancer. The company's approach aligns with broader industry trends toward noninvasive, multiomic diagnostics that enable earlier intervention. Success in this space could position ClearNote Health as a key player in the evolving landscape of precision oncology.
What we're watching
- Clinical Validation
- Whether the 5hmC signature data will hold up in larger, more diverse patient populations beyond the BRCA-positive cohort.
- Regulatory Pathway
- The pace at which ClearNote Health can secure FDA approval for its Avantect Test, currently used under CLIA certification.
- Commercialization Strategy
- How ClearNote Health will position its test within the growing market for liquid biopsy and early cancer detection technologies.
Related topics